adult T-cell lymphoma

Trending

View All

Pharma News for Sangamo, Santen, and Eli Lilly

Sep 27, 2022

Daiichi Sankyo’s Ezharmia; Pfizer & Sangamo Hemophilia A Gene Therapy Trial; Approval for Fennec’s Pedmark; FDA Approves UBE and Santen’s OMLONTI; EC Approves AstraZeneca’s Tezspire; FDA Approves Selpercatinib; FDA Grants Accelerated Approval to Eli Lilly’s Retevmo; GSK & Spero Announce Exclusive License Agreement

Daiichi Sankyo Receives the First Approval for its Blood Cancer Drug Ezharmia Daiichi Sankyo has received the first global approval for Ezharmia, a first-in-class dual EZH1 and EZH2 inhibitor for the treatment of patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATL). The Japanese Ministry of ...

Find More

Editor's Pick

Wainua – The Only Approved Medicine for hATTR-PN Treatment

lyfgenia-or-casgevy-for-sickle-cell-disease-treatment

Lyfgenia or Casgevy: Who Will Lead the Sickle Cell Disease Treatment Space?

Another Feather in the Cap for Xtandi and Keytruda — The Two Main Cancer Drugs

vabysmo-for-retinal-vein-occlusion-treatment

Roche’s Vabysmo Third US Approval Spiced Up the Battle With Regeneron and Bayer’s Eylea

AAV Gene Therapies for Hemophilia B Treatment: The Road to a Cure

Newsletter/Whitepaper

ASCO Conference 2023

The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.

Catch the Glimpse here

By DelveInsight

adult T-cell lymphoma

Search by Categories

Our expertise in the industry

View All

Editor's Pick

Newsletter/Whitepaper

ASCO Conference 2023